Activation of Peroxisome Proliferator–Activated Receptor-α Protects the Heart From Ischemia/Reperfusion Injury
- 11 November 2003
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 108 (19), 2393-2399
- https://doi.org/10.1161/01.cir.0000093187.42015.6c
Abstract
Peroxisome proliferator-activated receptor-alpha (PPAR-alpha) is expressed in the heart and regulates genes involved in myocardial fatty acid oxidation (FAO). The role of PPAR-alpha in acute ischemia/reperfusion myocardial injury remains unclear. The coronary arteries of male mice were ligated for 30 minutes. After reperfusion for 24 hours, ischemic and infarct sizes were determined. A highly selective and potent PPAR-alpha agonist, GW7647, was administered by mouth for 2 days, and the third dose was given 1 hour before ischemia. GW7647 at 1 and 3 mg x kg(-1) x d(-1) reduced infarct size by 28% and 35%, respectively (P<0.01), and myocardial contractile dysfunction was also improved. Cardioprotection by GW7647 was completely abolished in PPAR-alpha-null mice. Ischemia/reperfusion downregulated mRNA expression of cardiac PPAR-alpha and FAO enzyme genes, decreased myocardial FAO enzyme activity and in vivo cardiac fat oxidation, and increased serum levels of free fatty acids. All of these changes were reversed by GW7647. Moreover, GW7647 attenuated ischemia/reperfusion-induced release of multiple proinflammatory cytokines and inhibited neutrophil accumulation and myocardial expression of matrix metalloproteinases-9 and -2. Furthermore, GW7647 inhibited nuclear factor-kappaB activation in the heart, accompanied by enhanced levels of inhibitor-kappaBalpha. Activation of PPAR-alpha protected the heart from reperfusion injury. This cardioprotection might be mediated through metabolic and antiinflammatory mechanisms. This novel effect of the PPAR-alpha agonist could provide an added benefit to patients treated with PPAR-alpha activators for dyslipidemia.Keywords
This publication has 25 references indexed in Scilit:
- Inhibition of Nuclear Factor Kappa B (NF-B):: An Emerging Theme in Anti-Inflammatory TherapiesMolecular Interventions, 2002
- A Role for Peroxisome Proliferator-activated Receptor α (PPARα) in the Control of Cardiac Malonyl-CoA LevelsJournal of Biological Chemistry, 2002
- Hypoxia in Vivo Decreases Peroxisome Proliferator-Activated Receptor α-Regulated Gene Expression in Rat HeartBiochemical and Biophysical Research Communications, 2001
- Inhibition of transcription factor NF-κB reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cellsCardiovascular Research, 2001
- Identification of a subtype selective human PPARα agonist through parallel-array synthesisBioorganic & Medicinal Chemistry Letters, 2001
- Induction of IκBα Expression as a Mechanism Contributing to the Anti-inflammatory Activities of Peroxisome Proliferator-activated Receptor-α ActivatorsPublished by Elsevier BV ,2000
- Deactivation of peroxisome proliferator–activated receptor-α during cardiac hypertrophic growthJCI Insight, 2000
- A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator- activated receptor alpha- deficient mice.JCI Insight, 1998
- 13C and 31P NMR Studies on the Effects of Increased Plasma Free Fatty Acids on Intramuscular Glucose Metabolism in the Awake RatPublished by Elsevier BV ,1997
- PROPOSED METABOLIC VICIOUS CIRCLE IN PATIENTS WITH LARGE MYOCARDIAL INFARCTS AND HIGH PLASMA-FREE-FATTY-ACID CONCENTRATIONSThe Lancet, 1977